Evidence map›Paper›PMID 32528890›Full record

ArticleFrontiers in oncology2020

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.

Qitong Chen, Dengjie Ouyang, Munawar Anwar, Ning Xie, Shouman Wang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo and 28 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04646759 (Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04646759 phase3recruitingnot on this map

Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer: A Multicenter, Randomized, Phase III Study

TypeinterventionalSponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRan2020 to 2030Enrolled516ConditionsBreast CancerArmsFulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 13 institutions in 1 country.

Qitong ChenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Dengjie OuyangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Munawar AnwarDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ning XieDepartment of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shouman WangDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
Peizhi FanDepartment of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
Liyuan QianDepartment of Breast and Thyroid Surgery, Central South University Third Xiangya Hospital, Changsha, China.
Gannong ChenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Enxiang ZhouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Lei GuoDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xiaowen GuDepartment of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
Boni DingDepartment of Breast and Thyroid Surgery, Central South University Third Xiangya Hospital, Changsha, China.
Xiaohong YangDepartment of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China.
Liping LiuDepartment of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China.
Chao DengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhi XiaoDepartment of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Jing LiDepartment of Breast Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China.
Yunqi WangDepartment of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China.
Shan ZengDepartment of Internal Medicine - Oncology, Xiangya Hospital Central South University, Changsha, China.
Jinhui HuDepartment of Breast Surgery, The First Hospital Hunan University of Chinese Medicine, Changsha, China.
Wei ZhouDepartment of Breast and Thyroid Surgery, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China.
Bo QiuDepartment of Oncology, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China.
Zhongming WangDepartment of Breast Surgery, The Third People's Hospital of Yongzhou, Yongzhou, China.
Jie WengDepartment of Oncology, The First People's Hospital of Yueyang, Yueyang, China.
Mingwen LiuDepartment of Breast and Thyroid Surgery, The First People's Hospital of Xiangtan City, Xiangtan, China.
Yi LiDepartment of Oncology, The Third People's Hospital of Changde, Changde, China.
Tiegang TangDepartment of Oncology, Xiangtan Central Hospital, Xiangtan, China.
Jianguo WangDepartment of General Surgery, Xiangtan Central Hospital, Xiangtan, China.
Hui ZhangDepartment of Oncology, Central Hospital of Shaoyang, Shaoyang, China.
Bin DaiDepartment of Breast and Thyroid Surgery, Central Hospital of Shaoyang, Shaoyang, China.
Wuping TangDepartment of Breast Surgery, Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, China.
Tao WuDepartment of Oncology, The First People's Hospital of Changde, Changde, China.
Maoliang XiaoDepartment of Oncology, The Third Hospital of Hunan University of Chinese Medicine, Zhuzhou, China.
Xiantao LiDepartment of Oncology, The Central Hospital of Yiyang, Yiyang, China.
Hailong LiuDepartment of Internal Medicine - Oncology, The First People's Hospital of Chenzhou, Chenzhou, China.
Lai LiDepartment of Breast and Thyroid Surgery, The People's Hospital of Xiangtan County, Xiangtan, China.
Wenjun YiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Quchang OuyangDepartment of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Central South University · CNThe Central Hospital of Shaoyang · CNHunan Provincial People's Hospital · CNSecond Xiangya Hospital of Central South University · CNThe First People's Hospital of Changde · CNXiangya Hospital Central South University · CNXiangyang Central Hospital · CNChangzhou Third People's Hospital · CNChenzhou First People's Hospital · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CNHunan University · CNThird Xiangya Hospital · CNYueyang Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerHER2metastasespyrotinibtumor mutation burden

Identifiers

PMID32528890
PMCPMC7263174
OpenAlexW4241868283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.